3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Veronica Wu of First Bight Ventures, BJ Schaknowski of symplr, and Mikyoung Jun of the University of Houston. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know — the first of this new year — I'm introducing you to three local innovators across industries — from health care innovation to energy — recently making headlines in Houston innovation.

Veronica Wu, founder of First Bight Ventures

Veronica Wu, who moved to Houston from Silicon Valley last year, has launched a new venture capital firm to help accelerate synthetic biology startups. Photo courtesy of First Bight Ventures

Veronica Wu is a relative newcomer to Houston. She made the move from Silicon Valley to the Bayou City in the middle of 2021. Wu has announced the launch of First Bight Ventures, a new VC firm focused exclusively on early-stage synthetic biology startups, and based right here in Houston. She plans to leverage the local market to incubate these startups locally, according to the release.

“Houston is well positioned to become a major center for synthetic biology with its existing talent, industries, and capital," she says.

Wu has over 20 years of experience in managerial positions at tech companies like Apple, Tesla, and Motorola, and she served as a founding team member of McKinsey & Company’s Greater China office's business technology practice. Click here to read more.

BJ Schaknowski, CEO of symplr

Houston-based symplr has made another strategic acquisition as it grows its software offerings to its health care clients. Image via symplr.com

Symplr will acquire the Midas platform, which provides users with operations efficiency via data analytics, from New Jersey-based Conduent Incorporated (Nasdaq: CNDT). The deal, valued at $340 million, is expected to close in the first quarter of 2022.

"Midas Health Analytics Solutions brings actionable data and insights to help symplr's health system clients improve patient care and deliver better outcomes," says BJ Schaknowski, CEO of symplr, in a news release. "With integrated quality outcomes and machine learning-based advanced analytics, our combined compliance, quality and safety software portfolio can better predict patient specific risks, deliver population health insights, and proactively improve and support business intelligence performance further advancing symplr's mission of transforming healthcare operations." Click here to read more.

Mikyoung Jun, ConocoPhillips professor of data science at the UH College of Natural Science and Mathematics

A new UH-led program will work with energy corporations to prepare the sector's future workforce. Photo via UH.edu

The Data Science for Energy Transition project, which is funded through 2024 by a $1.49 million grant from the National Science Foundation, includes participation from UH, the University of Houston-Downtown, the University of Houston-Victoria, the University of Houston-Clear Lake, and Sam Houston State University.

At the helm of the initiative is principal investigator Mikyoung Jun, ConocoPhillips professor of data science at the UH College of Natural Science and Mathematics.

“It’s obvious that the Houston area is the capital for the energy field. We are supporting our local industries by presenting talented students from the five sponsoring universities and other Texas state universities with the essential skills to match the growing needs within those data science workforces,” Jun says in the release. “We’re planning all functions in a hybrid format so students located outside of Houston, too, can join in.” Click here to read more.

Houston-based symplr has made another strategic acquisition as it grows its software offerings to its health care clients. Image via symplr.com

Houston health tech company makes $340M deal to acquire analytics biz

m&a moves

A tech-enabled Houston health care operations business has announced another strategic acquisition that would close before the end of the quarter.

Houston-based symplr, which provides software solutions for governance, risk management, and compliance and is backed by California-based Clearlake Capital Group L.P. and Massachusetts-based Charlesbank Capital Partners, announced this week that it will acquire Midas Health Analytics Solutions. Symplr will acquire the Midas platform, which provides users with operations efficiency via data analytics, from New Jersey-based Conduent Incorporated (Nasdaq: CNDT). The deal, valued at $340 million, is expected to close in the first quarter of 2022.

Midas brings to the table a vast data warehouse with over 100 million claims and 30,000 indicators, according to the release, and comparative data from an estimated 800 hospitals.

"As part of our strategy to streamline our portfolio, we consider divestitures of select businesses in order to enhance shareholder and client value." says Cliff Skelton, Conduent president and CEO, in the release. "We believe this is a mutually beneficial transaction and we are focused on providing a seamless transition for our clients. We are committed to delivering robust business process solutions to all industries, including the healthcare industry."

Symplr has been on a bit of a roll when it comes to acquisitions. In March, InnovationMap reported that the SaaS company acquired Phynd Technologies, and symplr went on to acquire another handful of companies throughout 2021. Looking back, symplr has made over a dozen acquisitions and was recognized among the fastest-growing tech companies by Deloitte in 2020.

"The Midas acquisition further strengthens symplr's comprehensive healthcare operations SaaS solutions that enable hospitals and health systems to efficiently navigate the complexities of integrating critical business operations," says Behdad Eghbali, co-founder and managing partner of Clearlake, which acquired symplr in 2018. "We look forward to supporting the company as it continues driving industry consolidation and accelerating organic growth through our O.P.S. value creation framework."

Houston-based symplr has acquired a Dallas SaaS company as it grows its software offerings to its health care clients. Image via symplr.com

Houston health care SaaS company makes strategic acquisition

keep it symplr

A Houston-based health tech company is on an acquisition roll — it's latest deal marks the 11th acquisition in six years.

Software-as-a-service company symplr, which makes health care governance, risk management, and compliance software, has acquired Dallas-based data management SaaS company, Phynd Technologies. Symplr, which is backed by Clearlake Capital Group L.P. and SkyKnight Capital, did not disclose the terms of the transaction.

Symplr's burst of M&A activity spurs from the growing company's mission of providing end-to-end healthcare GRC portfolio, according to a news release. Phynd's platform manages data to provider profiles, locations, clinical expertise, availability, and health plan and network participation.

"Delivering new and significant ongoing value to our customers is integral to symplr's mission. Bringing Phynd into the symplr family helps us further deliver on that promise," says BJ Schaknowski, CEO of symplr, in the news release. "Phynd will integrate with our existing provider software solutions to create an end-to-end provider data management platform for hospitals, health systems, and payers that is unmatched in the healthcare industry today. We're excited to continue leading the healthcare GRC industry with innovative solutions that drive meaningful change."

Phynd was founded in 2012 and raised its $8 million series B in January 2019, according to Crunchbase.

"In the digital healthcare era, organizations must manage their providers and locations as searchable products that are accessible by consumers, referring providers and staff, and care delivery and revenue cycle teams. The combination of symplr and Phynd offers a unique, holistic provider data management offering that includes all providers, locations and virtual visits, helping healthcare organizations become more efficient and competitive," says Tom White, CEO of Phynd, in the release.

"symplr now offers the most robust and scalable central hub of continuously-curated credentialed and referring provider data. We are enthusiastic about executing as one organization and jointly expanding symplr's market leadership," he continues.

The Phynd acquisition is the sixth since symplr formed its partnership with private equity firms Clearlake and SkyKnight in 2018. Based in Santa Monica and Dallas, Clearlake is focused on software solutions across industries and currently has approximately $30 billion of assets under management. San Francisco-based SkyKnight Capital manages over $1.5 billion of PE capital and invests in healthcare, insurance, and business services.

Last year, symplr was named to Deloitte's 26th annual North America Technology Fast 500.The companies on the list were selected based on percentage fiscal year revenue growth from 2016 to 2019. The company came in at No. 426 on the national list with 221 percent growth.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

How a Houston company is fighting anxiety, insomnia & Alzheimer’s through waveforms

mental health

A Houston-based company is taking a medicine-free approach to target brain neurologically associated with mental illness.

Nexalin Technology’s patented, FDA-cleared frequency-based waveform targets key centers of the midbrain to support the normalization of neurochemicals through a process known as Transcranial Alternating Current Stimulation (tACS). Delivered via a non-invasive device, the treatment gently stimulates the hypothalamus and midbrain, helping to “reset networks associated with symptoms” of anxiety and insomnia. Early clinical evidence suggests this approach can promote healthier brain function and improved sleep.

Through its recently appointed scientific advisory board (SAB), Nexalin also aims to target Alzheimer’s disease with a clinical development pipeline supported by published data and internal data from studies involving its proprietary DIFS technology. Nexalin’s Gen-2 SYNC and Gen-3 Halo headset delivers the DIFS, which is a waveform that can penetrate deep brain structures implicated in cognitive decline and mental illness.

The board includes experts in neurology, neuroimaging and neurodegenerative diseases with Dr. Mingxiong Huang, Dr. David Owens, and Dr. Abe Scheer coming on board. Nexalin plans to initiate new Alzheimer’s-focused clinical studies in the Q3 2025 by incorporating cognitive testing, imaging biomarkers, and guided metrics to assess treatment efficacy and neural activation.

“I am excited to work alongside Nexalin’s leadership and fellow SAB members to help guide the next generation of non-invasive neuromodulation therapies,” Huang said in a news release. “The intersection of neuroimaging, brain stimulation, and clinical science holds enormous potential for treating neurodegenerative disease.”

Recently, Nexalin’s proprietary neurostimulation device moved forward with a clinical trial that evaluated its treatment of anxiety disorders and chronic insomnia in Brazil. The first of Nexalin’s Gen-2 15-milliamp neurostimulation devices was shipped to São Paulo, Brazil, and the study will be conducted at the Instituto de Psiquiatria University Hospital (IPq-HCFMUSP). The shipments aim to support the launch of a Phase II clinical trial in adult patients suffering from anxiety and insomnia. The Nexalin Gen-2 15-milliamp neurostimulation device has also been approved in China, Brazil and Oman. Its Gen 1 device first received FDA clearance in 2003, according to the company's website.

The company also enrolled the first patients in its clinical trial at the University of California, San Diego, in collaboration with the VA San Diego Healthcare System for its Nexalin HALO, which looks to treat mild traumatic brain injury and post-traumatic stress disorder in military personnel and the civilian population.

Nexalin previously raised $5 million through a

public stock offering.

Houston innovation hub announces first cohort for energy-focused accelerator

Powering Up

Energytech Nexus, a Houston-based hub for energy startups, has named its inaugural cohort of 14 companies for the new COPILOT accelerator.

COPILOT partners with Browning the Green Space, a nonprofit that promotes diversity, equity and inclusion (DEI) in the clean energy and climatech sectors. The Wells Fargo Innovation Incubator (IN²) at the National Renewable Energy Laboratory backs the COPILOT accelerator.

The eight-month COPILOT program offers mentorship, training and networking for startups. Program participants will be tasked with developing pilot projects for their innovations.

Two Houston startups are members of the first COPILOT class:

GeoFuels, housed at Houston’s Greentown Labs, has come up with a novel approach to hydrogen production that relies on geothermal power and methane decomposition.
PolyQor, which converts plastic waste into eco-friendly construction materials. Its flagship EcoGrete product is an additive for concrete that enhances its properties while reducing carbon emissions. PolyQor’s headquarters is at Houston’s Greentown Labs.

Other members of the COPILOT cohort are:

Birmingham, Alabama-based Accelerate Wind, developer of a wind turbine for commercial buildings.
Ann Arbor, Michigan-based Aquora Biosystems, which specializes in organic waste biorefineries.
Phoenix-based EarthEn Energy, a developer of technology for thermo-mechanical energy storage.
New York City-based Electromaim, which installs small hydro-generators in buildings’ water systems.
Chandler, Arizona-based EnKoat, an advanced materials company whose flagship product, the IntelliKoat System, is a patented two-layer thermal and weather barrier roof coating for flat and low-slope commercial buildings.
Calgary, Canada-based Harber Coatings, which manufactures electroless nickel coating and electroless nickel plating.
Dallas-based Janta Power, which designs and makes 3D solar towers.
Miami-based NanoSieve, a developer of gas remediation technology.
Palo Alto, California-based Popper Power, which has developed a platform that turns streetlight networks into resilient, maintenance-free distributed charging infrastructure.
Buffalo, New York-based Siva Powers America, developer of small wind turbines for farms, utility companies and others with annual energy needs of 300,000 to 2 million kilowatt-hours.
Los Angeles-based Thermoshade, which specializes in cooling panels for outdoor environments.
Waukesha, Wisconsin-based V-Glass, Inc., developer of a vacuum-insulated glass for affordable high-efficiency windows.

“These startups reflect the future of energy access and resilience innovation,” said Juliana Garaizar, founding partner of Energytech Nexus. “By connecting them directly with partners through COPILOT, we’re helping them overcome the ‘pilot gap’ to build solutions that scale.”

The startups will run pilot projects along the Gulf Coast for their inventions.

Rice University's top innovation exec leaving for new role at UVA

moving on

Paul Cherukuri, Rice University's top innovation executive, responsible for some of Rice’s major innovative projects like the Rice BioTech LaunchPad and Rice Nexus, will leave the university next month to accept a position at the University of Virginia.

Cherukuri, Rice’s first vice president for innovation and chief innovation officer, will become the University of Virginia’s Donna and Richard Tadler University Professor of Entrepreneurship and the school's first chief innovation officer, according to a release from Rice. Cherukuri, who has served for more than 10 years at Rice, plans to depart his current position on Sept. 30.

Adrian Trömel, associate vice president for innovation strategy and investments at Rice, will serve as interim vice president for innovation and chief innovation officer after Cherukuri departs, and as the university starts an international search for his replacement.

“We appointed Paul to build an ambitious and high-functioning innovation operation, and he has succeeded remarkably in short order,” Rice President Reginald DesRoches said in the release. “In every area, from technology translation and startup creation to commercialization and entrepreneurship training, he has led the effort to vastly improve our structure, operations and relationships. He has contributed immensely both to our strategies and their implementation across numerous areas, and we’ll miss him greatly.”

Cherukuri is a physicist, chemist and medical technology entrepreneur, and has been a member of DesRoches’ leadership team since 2022. Cherukuri served as executive director of Rice’s Institute of Biosciences and Bioengineering from 2016 to 2022, where he helped in the development of interdisciplinary translational research partnerships with federal and corporate agencies. His work helped earn nearly $37 million in funding for accelerating the development of new technologies into commercial products. In the energy transition field, Cherukuri led a $12.5 million partnership with Woodside Energy to transform greenhouse gases into advanced nanomaterials for next-generation batteries and transistors.

Initiatives the Rice Biotech Launch Pad, an accelerator focused on expediting the translation of the university’s health and medical technology; RBL LLC, a biotech venture studio in the Texas Medical Center’s Helix Park dedicated to commercializing lifesaving medical technologies from the Launch Pad; and Rice Nexus, an AI-focused "innovation factory" at the Ion; were all launched under Cherukuri’s leadership. With his work at the Ion, Cherukuri also led the announcement of a partnership with North America’s largest climate tech incubator, Greentown Labs.

“I am proud of the relentless innovative spirit we have built for Rice in Houston and around the world,” Cherukuri said in the release. “I look forward to bringing new energy and vision to UVA’s efforts in this critical space for our country, its success and future.”

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME